Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

Abstract

Objectives The aim of the study was to compare incidence rates (IRs) of AIDS/death in patients with and without treatment interruption (TI) of combination antiretroviral therapy (cART) for periods of 3 months or more for different categories of CD4 cell count and viral load, and to determine risk factors for clinical progression to AIDS/death. Methods Patients starting cART with a CD4 cell count and a viral load available within 6 months of starting cART were included in the study. The IR and risk factors of TI were determined. We assessed the incidence rate ratios (IRRs) for TI and AIDS/death events using Poisson regression models. Results Of 3811 patients included in the study, 26% were ART‐naïve prior to cART. The median date of starting cART was July 1997, the median CD4 cell count was 226 cells/μL and the median viral load was 4.36 log₁₀ HIV‐1 RNA copies/mL. We observed 1243 interruptions and 403 AIDS‐events/deaths. The IR of AIDS/death was higher in patients with lower CD4 cell counts or higher viral loads, regardless of TI. After adjusting for baseline factors, the IR of AIDS/death was significantly higher in the TI group than in the non‐TI group [IRR 2.63; 95% confidence interval (CI) 2.01–3.44; PP=0.37). Within the TI group, patients with a current CD4 cell count of 350 cells/μL had a 4‐fold lower risk of disease progression. Conclusions TI is common in clinical practice. The risk of AIDS/death increased more than 2‐fold for patients stopping all cART regimen drugs for 3 months or more. Among patients experiencing a TI, those with low CD4 cell counts, high viral loads or prior AIDS had an increased risk of AIDS/death. Hence, TI should be discouraged and closely monitored if it occurs.